Background: Flavonoids are dietary plant compounds suspected to reduce the incidence of chronic diseases in several regions of the world. Due to anti-allergic and anti-inflammatory activities, apigenin (4',5,7,-trihydroxyflavone) is thought to interfere with crucial events in the pathomechanism of asthma. However, the effect of apigenin on TGF-b-induced fibroblast-to-myofibroblast transition (FMT) in human lung fibroblast populations, a key event in asthma progression, has not yet been addressed. Methods: Primary human bronchial fibroblasts (HBFs) propagated from ex vivo bronchial biopsies derived from patients with diagnosed asthma and human embryonic lung IMR-90 fibroblasts were cultured in vitro and treated with TGF-b and apigenin. The myofibroblast fraction in fibroblast populations was evaluated by immunocytochemistry. Expression of a-smooth muscle actin (a-SMA) and tenascin C were assessed at the mRNA and protein level by real-time RT-PCR and immunoblotting, respectively. Additionally, proliferation and viability tests and time lapse-monitoring of movement of individual HBFs and IMR-90 cells were evaluated. Results: We show that apigenin attenuates TGF-b -induced FMT in cultures of HBFs, and the magnitude of this attenuation was found to be similar to that observed in the established cell line of lung IMR-90 fibroblasts. Notably, FMT inhibition was observed at low (~10 µM), non-cytotoxic and non-cytostatic apigenin concentrations and could be correlated with the inhibition of a-SMA and tenascin C expression in HBFs at the mRNA level. Conclusions: Our data are the first to demonstrate that apigenin inhibits the TGF-b -induced expansion of hyper-contractile, a-smooth muscle actin -positive myofibroblasts within populations of HBFs derived from asthmatic patients. They also indicate the possible interference of apigenin with bronchial wall remodeling during the asthmatic process in vivo.
